Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood|July 29, 2010
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)Sylvain Thepot, Raphael Itzykson, Valerie Seegers, et al.
Nature Communications|December 22, 2018
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subsetDorothée Selimoglu-Buet, Julie Rivière, Hussein Ghamlouch, et al.
Haematologica|July 10, 2025
Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthoodFlorian Chevillon, Elsa Labrune, Emmanuelle Clappier, et al.
Blood|March 17, 2024
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G CommitteeFrancesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Communications Biology|November 23, 2024
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathwaysDonia Hidaoui, Audrey Porquet, Rabie Chelbi, et al.
Cytometry. Part B, Clinical Cytometry|November 27, 2024
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemiaKim Pacchiardi, Victoire de Marcellus, Tony Huynh, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Leukemia Research|November 22, 2019
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasAline Massé, Louise Roulin, Justine Pasanisi, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood|July 29, 2010
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)Sylvain Thepot, Raphael Itzykson, Valerie Seegers, et al.
Nature Communications|December 22, 2018
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subsetDorothée Selimoglu-Buet, Julie Rivière, Hussein Ghamlouch, et al.
Haematologica|July 10, 2025
Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthoodFlorian Chevillon, Elsa Labrune, Emmanuelle Clappier, et al.
Blood|March 17, 2024
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G CommitteeFrancesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Communications Biology|November 23, 2024
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathwaysDonia Hidaoui, Audrey Porquet, Rabie Chelbi, et al.
Cytometry. Part B, Clinical Cytometry|November 27, 2024
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemiaKim Pacchiardi, Victoire de Marcellus, Tony Huynh, et al.
Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.
Blood Advances|May 19, 2023
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA studyLoïc Vasseur, Laurène Fenwarth, Jérôme Lambert, et al.
Leukemia Research|November 22, 2019
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasAline Massé, Louise Roulin, Justine Pasanisi, et al.
Pageof 10